Skip to content

Study · Not a test of the peptide alone · 1998

3 results

[Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats].

Iasnetsov VV, Krylova IN, Provornova NA

Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine1 Jan 1998Cited by 1 (Europe PMC)

PMID9606516 (opens in a new tab)PepBankPUB-09606516
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semax.

  1. 01AnimalNot a test of Semax aloneAnimal study (in vivo)Efficacy outcome

    In rats with bilateral carotid occlusion, a group of agents that included semax and the NMDA antagonist MK-801 significantly increased survival.

    In plain wordsIn rats, a group of nootropic drugs that included semax increased survival after carotid artery blockage.

    Peptide
    Semax
    Outcome
    IncreaseSurvival after bilateral carotid artery occlusion
    Study

    ratn: not reported in source

    Bilateral occlusion of the common carotid arteries
    Outcome group
    Mortality · Nervous system and cognition

    Source sentences

    Summary
    nootropic substances, i.e. sodium hydroxybutyrate, pyracetam, oxyracetam, aniracetam, centrophinoxine, nooglutyl, mexydol, semax, amide L-pyroglutamyl-D-alanine, and MK-801, a specific noncontesting antagonist of the NMDA-receptor complex, significantly increased survivability of the animals followi…

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

  2. 02AnimalNot a test of Semax aloneAnimal study (in vivo)Efficacy outcome

    In rats with bilateral carotid occlusion, the group of nootropics that included semax partly or completely prevented memory disorders.

    In plain wordsIn rats, a group of nootropic drugs that included semax partly or fully prevented memory problems after carotid artery blockage.

    Peptide
    Semax
    Outcome
    DecreaseMemory disorders after carotid occlusion
    Study

    ratn: not reported in source

    Bilateral occlusion of the common carotid arteries
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The nootrops prevented, partly or completely, mnestic disorders in the experimental rats.
    1 context sentence
    Summary · context
    nootropic substances, i.e. sodium hydroxybutyrate, pyracetam, oxyracetam, aniracetam, centrophinoxine, nooglutyl, mexydol, semax

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

  3. 03AnimalNot a test of Semax aloneAnimal study (in vivo)Efficacy outcome

    In rats with hypoxic amnesia, the group of nootropics that included semax fully or to a considerable extent blocked memory disorders, except N-acetylglycine amide and amide L-pyroglutamyl-D-alanine.

    In plain wordsIn rats with oxygen-lack amnesia, most of a group of nootropic drugs that included semax blocked memory problems.

    Peptide
    Semax
    Outcome
    DecreaseMemory disorders in hypoxic amnesia
    Study

    ratn: not reported in source

    Hypoxic amnesia
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Except for N-acetylglycine amide and amide L-pyroglutamyl-D-alanine, the nootrops fully or to a considerable extent blocked the development of mnestic disorders in hypoxic rats.
    1 context sentence
    Summary · context
    nootropic substances, i.e. sodium hydroxybutyrate, pyracetam, oxyracetam, aniracetam, centrophinoxine, nooglutyl, mexydol, semax

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 12Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 9 times, first on 21 Oct 2026, 15:59 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 17:28 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.